Phase 2b LUMINA 2 study data support rilzabrutinib's FDA Breakthrough Therapy designation for the treatment of warm autoimmune hemolytic anemia. The Food and Drug Administration (FDA) has granted ...

The following report presents 3 cases of intravascular hemolysis that followed aortic-valve replacement with cusps composed of Dacron cloth impregnated with silicone rubber. 8,9 Hematologic data on 32 ...

This paper demonstrates a previously undescribed defect of a glycolytic enzyme, triosephosphate isomerase, in the erythrocytes and leukocytes of a patient with congenital hemolytic anemia. The carrier ...

Cold antibody hemolytic anemia is a rare autoimmune disorder characterized by the premature destruction of red blood cells by autoantibodies at temperatures of approximately 0 to 10 degrees Celsius. Q ...

Mihir Raval, MD, MPH, comments on the difference between cold agglutinin disease and other autoimmune hemolytic anemias. Neil Minkoff, MD: Now, you had mentioned that there are other autoimmune ...

Additional population-based studies of autoimmune hemolytic anemia and its management are needed to reduce mortality in this patient population. Autoimmune hemolytic anemia (AIHA) is typically a ...

Johnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA), seeking approval of IMAAVY® ...

CAR T-cell therapies are now being used to treat patients with B-cell driven autoimmune diseases such as lupus. Another such condition is autoimmune hemolytic anemia, in which immune cells destroy red ...

Physical/chemical causes. These causes of hemolysis are most often secondary to improper handling of blood products. Reasons include inadvertent heating or freezing with subsequent thawing of the red ...

Autoimmune hemolytic anemia (AIHA) and paroxysmal nocturnal hemoglobinuria (PNH) are distinct blood disorders with different underlying causes and treatment approaches. Each is rare and potentially ...